Shanghai Junshi Biosciences: A Real PD-1 Franchise, But the A-Shares Already Price an Unproven Profit Bridge

The right qualitative label is a company in transition. Junshi is past the phase where its fate depends on whether it can invent or approve a lead drug. It is now in the phase where market value depends on whether one successful franchise can finance the next wave of assets without excessive dilution. That is a healthier place than Junshi occupied three years ago, but not yet a high-quality compounding model. The transition is visible in the numbers, in the partner roster, and in the balance sheet: cash plus trading financial assets reached CNY 4.56 billion at the end of Q1 2026, but gross debt had also climbed to roughly CNY 5.98 billion, leaving Junshi better funded than before but not yet self-funding in the way mature biopharma investors prefer.

That leaves the stock in a specific place today. The fundamentals are materially stronger than the equity market used to assume, the toripalimab franchise is commercially real, and the company has shown it can license globally instead of trying to build every market itself, though the path to breakeven is credible but still not fully proven on a recurring basis. In capital-markets terms, the A share no longer looks like a distressed biotech, yet it also does not offer the clean margin of safety that would justify treating Junshi as an undisputed bargain. The business has improved faster than the bear case allows. The stock has already recovered enough that the bull case now needs cleaner earnings quality, not just faster sales growth.

Company vertical history

Origins and why Junshi existed

Junshi was founded in Shanghai in December 2012, at a moment when China’s biopharma industry was shifting from generic manufacturing toward innovative biologics. The company’s own description stresses an innovation-driven model built around discovery, development, manufacturing, and commercialization, rather than contract services or generic imitation. That founding choice shaped everything that followed: Junshi was built to own molecules, not to fill capacity.

The founder-control structure also mattered. Company disclosures identify Junshi as ultimately controlled by chairman Xiong Jun and his father Xiong Fengxiang. The annual report shows Xiong Jun’s background as a finance-trained entrepreneur rather than a career bench scientist, while early operating leadership included experienced medical and drug-development executives such as Li Ning. That combination helps explain the company’s character. Junshi’s story has always mixed scientific ambition with an unusually capital-markets-aware willingness to list early, raise repeatedly, and license regionally when needed.

The problem Junshi first set out to solve was not abstract. China had a large oncology burden, but innovative immuno-oncology therapies were still largely imported and expensive. Toripalimab’s eventual launch as the first domestically developed anti-PD-1 antibody approved in China addressed exactly that gap. The founding thesis was that a Chinese developer could build globally relevant biologics and also win on health-economics grounds in its home market. That thesis has held up better than many early China-biotech pitch decks did.

Listing path and the first capital-markets story

Junshi’s listing path was unusual and important. The company first came public in Hong Kong on 2018-12-24 under Chapter 18A, one of the early pre-revenue biotech names on the market. The IPO priced at HKD 19.38 per H share. Junshi issued 158.91 million H shares for gross proceeds of HKD 3.08 billion, and the over-allotment option was later fully exercised for another 23.84 million shares and HKD 462 million of gross proceeds. Contemporary deal materials and transaction summaries put the final fundraising size at roughly $453 million after the greenshoe.

The first capital-markets story was simple: Junshi was not being sold as a profitable pharmaceutical company, but as one of the first Chinese innovative-biologics names capable of building a proprietary checkpoint inhibitor franchise. That scarcity value was powerful in late 2018. On its Hong Kong debut, the stock closed about 22% above the IPO price.

The second act came with the STAR Market. On 2020-07-15, Junshi listed in Shanghai under ticker 688180 after delisting from the NEEQ and converting its shares for the STAR listing. It sold 87.13 million new A shares at RMB 55.50 each, raising about RMB 4.836 billion gross and roughly RMB 4.497 billion net. The story told to A-share investors was bigger than Hong Kong’s 18A scarcity pitch. It was “Chinese innovative drug champion with a first-in-class domestic PD-1 and a global pipeline.” The STAR Market rewarded that story at materially richer multiples than Hong Kong did.

Stage division

Junshi’s history is best divided into four stages.

The first stage ran from founding through the Hong Kong IPO, a platform-building period of discovery capability, clinical progression, and fundraising around the promise of toripalimab. Revenue quality mattered little; scientific legitimacy and access to capital mattered a great deal. The market priced Junshi as a rare asset in an immature sector.

The second stage, running from late 2018 through the STAR listing and the first domestic commercialization wave, turned on toripalimab’s launch as China’s first domestic PD-1, which gave Junshi a genuine commercial anchor. That changed the business model from “future molecule owner” to “company with a first product and a commercialization challenge.” The company still burned cash heavily, but the market began to believe the core asset could be more than a single-approval event.

Globalization, frustration, and then validation defined the third stage, running from 2021 through 2023. In 2021, Junshi licensed U.S. and Canada rights to Coherus, taking a large upfront payment and outsourcing commercialization. That was a mature decision: it monetized overseas ambition without pretending Junshi could build a U.S. commercial infrastructure alone. But in 2022 the FDA issued a complete response letter for toripalimab, citing a quality process change and the need for on-site inspections in China, which had been hindered by COVID-era travel restrictions. That setback mattered because it punctured the easy narrative that Chinese innovation could move abroad without regulatory friction. The approval finally came in October 2023, making LOQTORZI the first U.S.-approved Chinese-developed and Chinese-manufactured innovative biologic. In hindsight, the CRL was not fatal to the franchise, but it did permanently remind investors that “global” in biotech still means quality systems, inspections, and regulatory stamina, not just data.

The fourth stage is the present one, beginning in 2024 and still unfolding: an efficiency-and-monetization stage. Management tightened spending, narrowed losses, pushed toripalimab through more label expansion, signed more regional licensing deals, placed 41 million new H shares in 2025 to strengthen liquidity, and is now trying to prove that better commercial scale can carry a still-active research engine into recurring profitability. The result is a very different Junshi from the one public investors met in 2018, less romantic and more measurable. That is progress, even if it leaves less room for narrative-only valuation.

Key nodes that still matter today

Toripalimab’s original China approval in December 2018 was the first key node, and its significance was larger than one drug: it established Junshi as the first domestic anti-PD-1 success story and gave the company a commercial identity that still defines it. That node remains underrated only if one forgets how much current revenue concentration still flows from it.

The second came in February 2021, when Junshi struck its U.S. and Canada collaboration with Coherus. Coherus obtained exclusive rights and responsibility for commercial activities in those territories, while Junshi received a $150 million upfront payment. This changed Junshi from a company trying to globalize alone into one willing to globalize through partners, a template that later reappeared in Europe, Latin America, and MENA. It still matters because it is the only practical way Junshi can monetize broad global reach without recreating the cost base of a multinational pharma company.

Then came the 2022 FDA CRL. It damaged confidence, delayed foreign monetization, and reinforced the discount global investors place on China-based manufacturing and inspection risk. Yet the later 2023 FDA approval also made the lesson more valuable: Junshi can clear a hard regulatory path, but not without delay. That history should temper both excessive optimism and excessive skepticism about future overseas filings.

The June 2025 H-share placement was the fourth. Junshi placed 41 million new H shares at HKD 25.35, raising about HKD 1.039 billion gross and approximately RMB 937 million net. The market instinctively reads biotech equity issuance as a weakness; in Junshi’s case, it was both dilution and insurance. It strengthened funding just as the company was trying to bridge toward breakeven, but it also reminded investors that the business had not yet earned complete capital independence. That nuance still matters to valuation.

Fifth was the March 2026 NMPA acceptance of NDAs for subcutaneous toripalimab across 12 indications. Commercially, the significance is convenience, site capacity, and life-cycle management rather than a brand-new mechanism; strategically, it matters because Merck and Bristol Myers are also using subcutaneous formulations to defend PD-1 franchises. As of the research date, Junshi still publicly describes JS001sc as accepted rather than approved, and still lists it in the development pipeline rather than marketed products. The likely timeline to approval is late 2026 to early 2027 if reviewed on a standard timetable, but that timing is an inference from NMPA review norms, not a company-guided date.

Financial vertical review

The financial arc has been cleaner than the stock narrative. Junshi’s 2025 revenue rose to CNY 2.498 billion, with product sales at CNY 2.301 billion, technical license and royalty income at CNY 161 million, and other revenue at CNY 36 million. The mix already tells the story: Junshi is no longer almost entirely dependent on financing, but it is still far from diversified. Product revenue is the engine; licensing is helpful but not yet transformative.

Loss quality improved in 2025. Gross margin was supported by higher product sales and lower unit costs, while management cut administrative expense and held selling expense growth far below product-sales growth. R&D still rose modestly to CNY 1.342 billion, but as a share of revenue it fell to 53.72% from 65.45%. The business reason is straightforward: toripalimab’s commercial base is now big enough that fixed research and overhead absorb better. That is real operating leverage.

Cash conversion has improved but remains imperfect. In 2025, operating cash outflow narrowed sharply to negative CNY 519.6 million from negative CNY 1.434 billion in 2024, helped by higher commercial sales and receipt of licensing payments. That is a major improvement. It is still not what a mature biopharma cash machine looks like. Junshi remains a capital consumer, just a less aggressive one than before.

The balance sheet is workable, not pristine. At the end of 2025, cash was CNY 2.615 billion and asset-liability ratio was 51.09%. By Q1 2026, cash plus trading financial assets rose to about CNY 4.56 billion, but gross debt had also grown to about CNY 5.98 billion, including long-term borrowings and bonds. That leaves Junshi adequately funded for its current plan, but not with the kind of surplus cash that would insulate investors if commercialization or partnering were to disappoint.

Price and valuation history

Junshi’s capital-markets history splits into clear phases. The Hong Kong IPO phase priced scarcity. The STAR Market phase priced domestic innovation euphoria. The 2021–2022 phase then punished regulation, dilution fears, and the broader biotech funding winter. The 2023 FDA approval repaired credibility but did not restore the old premium. The 2025–2026 phase has been about earnings-inflexion speculation.

The valuation center shifted because the business changed and because investor preference changed. In 2018 and 2020, Junshi could trade like a scarcity asset because there were few public China biotech names with a lead PD-1 and global ambition. In 2026, scarcity is gone. China has several public immuno-oncology names, and investors now ask whether a company in a crowded PD-1 field deserves a premium unless it shows differentiated profit conversion. The current A share being far above the H-equivalent price captures that split in real time.

Business model and moat

Revenue structure and what really pays the bills

Junshi’s 2025 revenue mix is unusually clean for a transitional biotech. Product sales accounted for CNY 2.301 billion of CNY 2.498 billion total revenue. Technical license and royalty income was CNY 161 million, and technical service and other revenue was CNY 36 million. Within product sales, toripalimab’s domestic sales were about CNY 2.068 billion. That means toripalimab alone represented roughly 83% of group revenue and about 90% of product sales. The company is more commercial than before, but it is still a one-franchise company in economic substance.

That concentration has two opposite implications. Positively, Junshi does not need a complex segment map to explain its economics; when toripalimab scales, the group scales. Negatively, one drug in a crowded PD-1 class still shoulders most of the valuation burden. The four marketed products in NRDL help broaden the base, but they have not yet changed the franchise hierarchy.

The ex-China piece should be read separately from China product sales. Junshi’s annual report explains that licensing and royalty income is recognized under technical licensing and sales-based royalty rules. Coherus books U.S. LOQTORZI sales directly, because Coherus is responsible for U.S. and Canada commercial activities. This is economically sensible but analytically important: growth from partner markets comes to Junshi as royalty and milestone-like revenue streams, not as the same kind of directly controlled product revenue that toripalimab generates inside China. Investors who treat all revenue as equally sovereign are overstating Junshi’s operating control.

Cost structure and operating leverage

Junshi’s cost structure is classic late-stage biotech. Manufacturing cost is meaningful but not the core swing factor. The real fixed-cost base is R&D, regulatory work, medical affairs, and commercial infrastructure. In 2025 sales expense rose only 6.95% while revenue rose 28.23%; management expense fell 5.50%; R&D rose 5.24%. That is exactly the pattern one wants to see when asking whether a commercial platform can outrun a legacy research burn.

The Q1 2026 numbers reinforced that pattern. Revenue grew 45.09% while R&D fell 19.42% and selling expense rose 11.6%. Junshi is clearly harvesting operating leverage from a larger commercial base and a more focused pipeline. The caution is that some quarterly profit improvement was helped by non-recurring items, so the operating-leverage conclusion is stronger than the “recurring profitability” conclusion.

Junshi still depends on continued R&D to defend relevance. This is not a consumer brand that can milk one SKU for a decade with small upkeep. If toripalimab stands still in a crowded checkpoint market, the moat weakens. The company must keep spending on life-cycle management, combinations, subcutaneous formulation, and second-generation assets such as JS207, JS212, JS213, and tifcemalimab. That means Junshi’s operating leverage is real, but structurally capped: some portion of every future gross-profit improvement must be reinvested back into competition-proofing the pipeline.

What the moat is, and what it is not

Junshi has three real moats, one partial moat, and one former moat that has decayed.

Regulatory and clinical execution in China-relevant immuno-oncology niches is the first real moat. Toripalimab was first domestically approved in China, has accumulated a broad set of mainland indications, and has won a distinct franchise position in nasopharyngeal carcinoma and several other tumor settings where Chinese patient populations and trial execution matter. This is not a broad “PD-1 is better than all peers” moat; it is a narrower execution moat in selected indications and geographies.

Regional licensing capability is the second. The verified roster of partnerships matters: Coherus in the U.S./Canada, Dr. Reddy’s across 21 Latin American countries, Hikma across 20 MENA countries, and LEO Pharma across 32 European countries. Junshi is not the only Chinese biotech to sign ex-China deals, but it has shown a repeatable ability to package one asset for multiple regional partners rather than waiting for a single global buyer. That is a commercial capability, not just a legal event, and it matters in a capital-constrained biotech market.

Junshi’s third real moat comes from integrated biologics infrastructure. It has built discovery, development, manufacturing, and commercialization capabilities, with R&D centers in the U.S., Shanghai, and Suzhou and an expanding production footprint. For a company of its size, that integration lowers dependence on third parties and helps it move molecules from bench to registry to launch with fewer organizational handoffs. It is not a deep scale moat versus Merck or Bristol Myers, but it is a meaningful capability moat versus smaller Chinese peer biotechs that still depend more heavily on outsourced pieces.

Partner-validated global credibility is the partial moat: FDA approval of LOQTORZI was a major proof point. It does not make Junshi a globally dominant company, but it does make future ex-China partnering easier because the company has crossed a regulatory threshold many Chinese biotechs have not. This moat is partial because it can help with deal-making and reputation, but it does not automatically solve commercialization or pricing pressure.

And then there is the moat that decayed: “first domestic PD-1.” That was once enough to command a premium; it is not enough today. In a field with multiple China-developed PD-1s and global incumbents, first-mover status no longer protects pricing or share by itself. Junshi still benefits from being first in the history books. It no longer benefits from being first in a competitively empty market.

Management and governance

Junshi remains founder-controlled. Disclosures identify Xiong Jun and his father Xiong Fengxiang as actual controllers. In Q1 2026, Xiong Jun held 90.2 million shares and Xiong Fengxiang held 41.1 million, while concert-party relationships extended that control block further. Investors should interpret Junshi as a controlled founder company, not a dispersed-shareholder governance model.

The most important recent management move was the 2024 handoff from long-time general manager Li Ning to Zou Jianjun as general manager and CEO, while Li Ning shifted toward vice-chairman and overseas responsibilities. That reflects the company’s changing needs. The old Junshi needed scientific and developmental credibility. The present Junshi needs commercial execution, global registration discipline, and sharper portfolio prioritization. On the evidence of 2025 and Q1 2026, management has improved cost control and commercial efficiency, but recurring profit quality still needs another few clean quarters before it deserves full trust.

On capital allocation, management’s record is mixed but improving. The Coherus partnership and later regional licensing deals were rational. The 2025 H-share placement was dilutive, but it bought time at a point when the company was not yet self-funding. Jul-2026’s licensing-out of roconkibart to Fosun Wanbang also suggests continuing willingness to monetize assets pragmatically rather than insist on owning every geography alone. The governance discount, if one exists, comes less from related-party abuse and more from the usual founder-controlled biotech risk: outside investors still rely heavily on management’s discipline in prioritizing what not to fund.

Industry and horizontal competitor analysis

Industry structure and cycle

Junshi sits in two overlapping industries: China innovative biopharma and the global PD-1 checkpoint market. Those industries are profitable in different places. In global oncology, the deepest profit pool still sits with large incumbents such as Merck and Bristol Myers, whose checkpoint franchises are embedded in broad trial networks, global payor negotiations, and extensive physician familiarity. In China innovative biopharma, the value pool is shifting. A few commercial-stage leaders can now self-finance more of their pipelines, while many smaller biotechs still depend on licensing or capital markets. Junshi is trying to move from the second bucket toward the first.

This is not a classic macro cycle. It is a regulatory cycle, a reimbursement cycle, a funding cycle, and a technology-iteration cycle. Demand for effective oncology therapies does not collapse with GDP. What changes sharply is pricing pressure, NRDL reimbursement breadth, trial standards, overseas regulatory access, and the availability of external capital. Junshi’s history fits that pattern exactly: the business survived the 2022–2024 biotech funding winter not because cancer demand fell or rose, but because commercialization strengthened while the company learned to rely more on partnerships than on valuation exuberance.

Policy, regulation, and geopolitics

Policy cuts both ways for Junshi. China’s NRDL inclusion is a material positive because it expands access and helps toripalimab volume growth; Junshi now says all four of its commercialized products are in the NRDL. At the same time, China’s oncology reimbursement framework limits the kind of pricing power that global investors might otherwise award to a broad PD-1 franchise. Volume can rise while unit economics remain constrained.

Overseas regulation is the other major variable. The 2022 FDA CRL and 2023 approval showed that Junshi can navigate the U.S. process, but only with a partner and only after a serious delay. That matters for every future overseas filing and for every investor tempted to assume that one U.S. approval means frictionless repeatability. Geopolitical risk here is not delisting drama. It is inspection, manufacturing, and supply-chain trust.

Horizontal comparison

Junshi’s closest useful comparison set is not one company but three layers.

China immuno-oncology peers such as Innovent and BeOne make up the first layer, and they show what scale looks like when a China biotech franchise broadens beyond one asset. BeOne’s 2025 TEVIMBRA sales were $737.3 million, up 18.8%, within a company that also has a global hematology franchise in BRUKINSA. Innovent’s 2025 results showed positive operating cash flow and EBITDA of RMB 1.99 billion, reflecting a far broader commercial base. Against those peers, Junshi is smaller, more concentrated, and less financially mature. Its advantage is that toripalimab’s domestic franchise strength is real and its overseas licensing path has been more explicit than some peers’. Its disadvantage is obvious: it has not yet built a second franchise with comparable economic weight.

China licensing-driven peers such as Akeso form the second layer. Akeso’s 2025 revenue reached RMB 3.033 billion, up 51.5%, and the market gives it a much richer valuation because ivonescimab has become a highly visible “platform plus licensing” story with stronger perceived global optionality. Junshi and Akeso are not interchangeable: Junshi’s core asset is a PD-1 monoclonal antibody in a crowded class, while Akeso’s flagship is a PD-1/VEGF bispecific that the market treats as more differentiated. That difference explains much of the valuation gap. Junshi is being valued as “proven but crowded, with pipeline upside.” Akeso is being valued more as “commercializing now, but potentially category-changing later.”

The global PD-1 benchmark makes up the third layer: Merck’s Keytruda and Bristol Myers’ Opdivo. Merck’s combined 2025 Keytruda/Keytruda Qlex sales were $31.68 billion. Bristol Myers’ 2025 Opdivo sales were $10.05 billion, plus $238 million from subcutaneous Opdivo Qvantig. Those numbers make the strategic point brutally clear: global checkpoint economics accrue to companies with scale, trial depth, and global infrastructure. Junshi is not competing with those names on breadth; it is competing where regional data, selected indications, local commercialization, and partnership economics can create viable niches. That can still be lucrative. It is not the same as a global PD-1 moat.

The numbers above are drawn from current market quotes and each company’s latest 2025-results disclosures; they are not fully apples-to-apples because Merck, BeOne, and Innovent are much broader enterprises than Junshi. The point is comparative shape, not false precision.

The business reason behind the differences is straightforward. Customers choose Merck and Bristol Myers because those companies have the deepest evidence bases and the broadest labels. Chinese hospitals choose Innovent or BeOne when those drugs are competitively positioned in reimbursement and clinical pathways. Junshi is chosen when toripalimab’s data package, approved indications, and price-access position line up well, especially in China-specific tumor settings. Investors, meanwhile, choose Akeso for upside asymmetry, BeOne for global scale, Innovent for operating maturity, and Junshi for a more specific transition thesis: a still-loss-making China biotech that may be crossing into self-sustaining economics through one major franchise plus selective ex-China monetization.

Ecologically, Junshi is best described as a challenger with one established franchise and several option assets. It is not the leader of global PD-1. It is not a niche microcap either. Its profit pool is taken most directly from China oncology spending and from the regional commercialization rights that global or regional partners are willing to pay for. The most likely way its position strengthens is if subcutaneous toripalimab improves franchise durability and if one next-wave asset becomes licensable or commercial. The most likely way it weakens is if PD-1 pricing compresses faster than new assets mature.

Current fundamentals and valuation analysis

What is happening in the last four quarters

Junshi’s last five reported quarters tell a coherent revenue story. In 2025, revenue moved from CNY 500.6 million in Q1 to 667.8 million in Q2, 637.5 million in Q3, and 692.5 million in Q4. Q1 2026 then rose to CNY 726.3 million. Net loss was negative in every 2025 quarter and still negative in Q1 2026, though far narrower on the headline number than a year earlier. Operating cash flow was negative in all four 2025 quarters but positive in Q1 2026, which is exactly what a late-stage transition into profitability is supposed to look like before it fully arrives.

The market reaction has focused on the apparent breakeven inflection, but the quality of that inflection is uneven. Product sales are genuinely accelerating. Toripalimab domestic sales were about CNY 6.23 hundred million in Q1 2026, up 39.37%. R&D intensity also fell sharply as a share of revenue. Yet the quarter’s statutory profit quality was flattered by non-recurring gains. Investors who focus only on the CNY 20.6 million headline loss are missing the fact that recurring profitability has not yet been demonstrated on a clean basis.

The near-term pipeline and regulatory tape has also stayed active. By Jul-2026, toripalimab had reached 13 approved indications in mainland China after the approval for first-line HER2-expressing urothelial carcinoma, while the subcutaneous JS001sc filing remained at NDA-accepted stage. The company’s July 2026 disclosures also showed continued filing activity for perioperative NSCLC and a new China licensing deal for roconkibart with Fosun Wanbang. The message is that Junshi is not managing for a single quarterly beat. It is trying to prove a repeatable model of “commercial cash generation plus selective asset monetization.”

What the market is trading now

The current A-share price is trading a narrowing-losses and future-profitability narrative much more than a pure pipeline narrative. The clearest evidence is the huge A/H premium. Hong Kong’s line prices Junshi closer to a still-risky biotech; Shanghai’s line prices it closer to an earnings-inflexion story. The market is effectively weighing two things at once: whether toripalimab can keep compounding domestically while partner markets add royalties, and whether that growth can happen fast enough to absorb research spending without new equity dilution.

The narrative may also be borrowing from sector-wide enthusiasm for licensing economics. Akeso’s external-validation story and the rising global appetite for Chinese biotech deal flow create a halo effect for names like Junshi. That is helpful for sentiment, but Junshi still needs more from its own numbers than from the sector mood. Unlike Akeso, Junshi’s valuation cannot be justified mainly by one perceived platform-disruption asset. It still stands or falls primarily on toripalimab economics.

Bull and bear divergence

The bull case starts with scale. Toripalimab’s domestic sales rose 37.72% in 2025 and about 39.37% in Q1 2026, while total revenue rose 28.23% in 2025 and 45.09% in Q1 2026. This is not what a saturating franchise looks like. If the product is still compounding at those rates after twelve mainland indications in 2025 and thirteen in 2026, bulls argue that life-cycle management and broader access still have room to run.

Junshi has also already solved part of the commercialization problem overseas by not trying to do everything itself: Coherus handles the U.S., Dr. Reddy’s handles Latin America, Hikma covers MENA, and LEO Pharma covers Europe. That is the right model for a company of this size. If partner execution is merely decent, Junshi can add higher-margin licensing and royalty streams without duplicating global SG&A.

The earnings bridge, too, is becoming credible: R&D as a share of revenue has fallen materially, operating cash burn has narrowed sharply, and Q1 2026 operating cash flow turned positive. A biotech that can grow revenue 45% while cutting R&D intensity is moving in the right direction.

The bear case starts with earnings quality. Q1 2026’s nearly breakeven headline was helped by non-recurring gains, while net profit excluding non-recurring items remained a loss of CNY 143.6 million. That is a fundamental bear point, not a pedantic accounting argument. Until Junshi posts multiple quarters of clean recurring profitability or near-profitability, the market is still paying partly for a forecast rather than fully for a fact.

Concentration is the second bear point. Toripalimab’s domestic sales were about CNY 2.068 billion in 2025, against total group revenue of CNY 2.498 billion. For all the talk of a 50-plus pipeline, the current economics are still highly dependent on one product in one crowded class, and if PD-1 pricing or competitive share weakens, group economics would feel it immediately.

Balance-sheet quality is the third concern. Junshi had CNY 4.56 billion of cash plus trading financial assets at Q1 2026, but roughly CNY 5.98 billion of gross debt. That is manageable, but it is not the profile of a company that can shrug off partner disappointments or clinical setbacks without consequence.

The fourth bear point is valuation asymmetry in the A line: the A share already trades at a very large premium to the H line and at a market cap that implies investors are willing to capitalize future success more generously than Hong Kong investors are. If the next few quarters deliver only incremental improvement rather than clean recurring profitability, that premium can compress even if the business itself continues improving.

Historical, peer, and absolute valuation

Historically, Junshi is no longer priced like a 2020 STAR-market concept stock, but it is also not cheap in a simple “commercial biotech on current sales” sense. Using the combined market capitalization of about CNY 31.65 billion and 2025 revenue of CNY 2.498 billion, the stock trades at roughly 12.7x trailing sales. That multiple is well below the kind of scarcity premium once attached to early China biotech, but it is still rich if one values Junshi only on current recurring earnings, because recurring earnings remain negative. The market is clearly paying forward for the 2027 earnings profile, not the 2025 one.

Peer comparison argues both ways. Against Akeso, Junshi looks cheaper because Akeso’s market cap versus 2025 revenue is far richer. Against BeOne, Junshi does not look obviously cheap because BeOne already has much broader scale and more diversified economics. Against Merck or Bristol Myers, P/S comparisons are uselessly flattering to Junshi because those companies convert sales into vast cash flows and shareholder returns. The right peer conclusion is that Junshi deserves a discount to Akeso’s option-premium multiple and a premium to a distressed biotech, but it has not yet earned the kind of broad-platform valuation that BeOne or a mature global pharma can carry.

Before using any method, the cash-flow passthrough needs to be checked. In 2025 Junshi’s operating cash outflow was negative CNY 519.6 million against a net loss attributable to shareholders of negative CNY 875.2 million, showing much better cash conversion than reported earnings suggest. But this is still a loss-making company, and owner earnings remain below accounting profit because capex and working-capital needs are still meaningful while recurring profit is not yet positive. That is why a forward owner-earnings framework and sales-based proxy are more sensible than headline P/E at this stage.

This scenario table is a research framework, not investment advice. It intentionally values Junshi on forward commercial and owner-earnings potential rather than on current P/E, because current recurring earnings are still negative. The table also explains why the stock is hard to call plainly cheap: the base case has upside, but the conservative case still sits below or around the current price.

Expectation-gap analysis is straightforward. The market is not pricing a collapse. It is pricing that Junshi can get close enough to recurring profitability over the next four to six quarters to deserve a much higher confidence multiple. What can break that expectation is not weak science; it is messy earnings quality. The next prints matter most for three variables: toripalimab domestic sales growth, recurring profitability excluding non-recurring items, and the pace at which licensing and royalty income becomes visible enough to matter.

On margin of safety, the conclusion is uncomfortable but clear. The current price is above the midpoint of the conservative scenario and sits inside the acceptable-hold zone for the base scenario. That means the margin of safety is not obvious. This is a good-company-improving case more than a bad-price-collapse case, but it is also not a “buy it regardless” case. An investor who wants a cushion should wait for a materially lower entry or for clearer evidence that recurring profitability is truly arriving.

Risk analysis

Toripalimab concentration is the biggest business risk, and I would rate it medium probability, high impact. Watch for a sustained drop in domestic sales growth below 15%, or evidence of price pressure once new competitors, combinations, or reimbursement adjustments bite. The transmission is immediate: slower toripalimab growth weakens revenue, erodes operating leverage, and makes the whole “crossing into profitability” narrative much harder to sustain.

Earnings-quality disappointment ranks second, and here both probability and impact are high. The indicator is simple: recurring net profit excluding non-recurring items stays materially negative while the headline net loss narrows only because of asset disposals, fair-value changes, or other one-offs. This risk transmits through confidence: in a stock already trading a sizable A-share premium, confidence erosion can hit the multiple before it hits revenue.

A third risk sits in partner execution outside China, medium probability and medium-to-high impact. Indicators are sparse, because Junshi does not directly disclose every partner-market sales detail each quarter, and that opacity is itself part of the risk. If it shows up, it will look like lower-than-expected royalties and milestones, which may not crater total revenue immediately but can materially weaken the valuation premium investors assign to “global licensing optionality.”

Balance-sheet pressure and eventual dilution come fourth, medium probability and medium impact. Watch net debt widening while recurring profit remains elusive. The mechanism is familiar in biotech: what begins as financing prudence becomes equity dilution or more expensive debt if cash generation does not catch up. The 2025 H-share placement was sensible, but it also showed that Junshi is not yet beyond capital-market dependence.

Fifth is regulatory delay for life-cycle management and next-wave assets, again medium probability and medium impact. JS001sc is the clearest near-term example: if the subcutaneous filing slips or comes with slower-than-expected review, investors lose a clean life-cycle extension catalyst right when Merck and Bristol Myers are also pushing subcutaneous formulations of their own checkpoint products.

Catalysts and tracking indicators

Positive catalysts are easy to name. The cleanest would be two consecutive quarters in which recurring profit excluding non-recurring items moves close to breakeven or positive while revenue growth remains above 25%. Approval of JS001sc would also matter, because it would extend toripalimab’s commercial life and align Junshi with the same franchise-defense playbook used by much larger PD-1 peers. A meaningful new ex-China licensing deal for a second asset would be the strongest proof that Junshi is building something broader than a one-franchise story.

Negative catalysts are just as concrete. A quarter in which toripalimab domestic sales growth drops sharply, a jump in debt without clean cash-flow conversion, or more quarters where headline profit improvement depends mainly on non-recurring items would all pressure the stock. So would any signal that partner markets are underperforming or that the subcutaneous filing is slipping beyond standard-review expectations.

The dashboard above is my tracking framework built from Junshi’s current financial base and disclosed regulatory milestones. The next earnings date is sourced from current market data pages; the operating figures come from the 2025 annual report and Q1 2026 report.

Key data tables

This table is the core of the Junshi debate. The top line is moving in the right direction fast, and cash burn is shrinking. The bottom line still depends too much on adjustments and one-offs to call the transition complete.

Cross-synthesis summary

Junshi’s full journey proves one capability above all others: it can take a Chinese-developed biologic from discovery to domestic commercialization and then into global regulatory markets through partnership rather than empire-building. That is not a trivial capability. Plenty of biotech companies can discover. Fewer can approve. Fewer still can approve, commercialize, survive a U.S. CRL, win eventual FDA approval, and then reshape themselves into a more disciplined operating model without losing the pipeline entirely. Junshi has done that. Its success was not luck, though luck always matters in drug development. It came from a genuine combination of molecule selection, clinical execution, capital access, and a management culture willing to partner regionally instead of insisting on doing too much alone.

What made that success possible still exists, but in altered form. The scientific engine and the regulatory execution ability are both still there, and the commercial base around toripalimab is stronger than three years ago. What has weakened is scarcity: Junshi no longer enjoys the empty-field advantage that “first domestic PD-1” once brought. Its real advantage now is sharper: selected oncology niches in China, proven ability to secure overseas partners, and a business mix that is at last large enough to create operating leverage. Its weakness is equally clear: the current economics are still too concentrated in one franchise, and the proof of recurring profitability is still incomplete.

The market’s most likely misjudgment is not about the direction of improvement. Junshi is improving. The harder question is the pace and cleanliness of the improvement. Bulls often overstate how close the company already is to recurring profitability by leaning on adjusted numbers. Bears often understate how materially the underlying business model has changed since 2023 by ignoring the growth in product sales, the narrowing cash burn, and the partner network Junshi has assembled. I think the better synthesis is this: the business has improved enough that treating Junshi like a perpetually cash-burning development biotech is too pessimistic, but the evidence is not yet clean enough to treat it like a self-funding high-quality compounder.

Over the next year, the critical variables are recurring profit quality, toripalimab domestic growth, and JS001sc review progress. Over three years, the crucial question is whether Junshi can build a second economically meaningful engine, whether through tifcemalimab, a licensing event around JS207/JS212/JS213, or some other asset that starts to dilute toripalimab concentration. Over five years, the question becomes whether Junshi can become a capital-light Chinese biotech with one internally commercialized China franchise and several externally monetized global assets. If that model works, the stock can deserve a better valuation. If it does not, Junshi will remain a company that is always “almost at breakeven” but never comfortably beyond it.

Junshi becomes a better investment under two conditions. The first is price: a materially lower entry would create a real margin of safety against execution noise. The second is evidence: if the company posts several quarters of recurring near-profitability or positive recurring profit, then investors would no longer need to pay today for a result that still sits partly in the future. The original judgment should be revisited if toripalimab domestic growth stalls sharply, if partner monetization disappoints despite approvals, or if rising debt and renewed dilution show that the business still cannot finance itself despite all the recent progress.

Bull and bear reasons

Bull reasons:

• Toripalimab’s domestic franchise is still expanding fast, with 2025 domestic sales up about 37.72% and Q1 2026 domestic sales up about 39.37%, an unusual growth rate for a label set this broad and already approved.
• Operating leverage is now visible: 2025 revenue rose 28.23% while R&D rose only 5.24% and management expense fell 5.50%, and Q1 2026 operating cash flow turned positive.
• Junshi has built a repeatable ex-China partnering model across the U.S./Canada, Latin America, Europe, and MENA, which can monetize global reach without building a global commercial cost base.
• FDA approval of LOQTORZI gives Junshi a regulatory credential many Chinese biotechs still lack, improving its credibility in future deal-making and overseas registration.
• JS001sc is a practical rather than speculative catalyst: if approved, it can defend the toripalimab franchise on convenience and site-efficiency grounds in the same way global PD-1 incumbents are defending their own franchises.

Bear reasons:

• Q1 2026’s headline near-breakeven was flattered by CNY 123.0 million of non-recurring gains, while recurring net profit ex non-recurring items remained a CNY 143.6 million loss.
• Toripalimab concentration is still extreme, at roughly 83% of 2025 group revenue, leaving Junshi highly exposed to one product in a crowded checkpoint category.
• The balance sheet is better funded but not yet conservative, with Q1 2026 cash plus trading financial assets of about CNY 4.56 billion versus gross debt of about CNY 5.98 billion.
• The A-share line embeds a very large premium over the H-share line, which leaves the stock exposed to multiple compression even if operations continue improving.
• The moat around being “first domestic PD-1” has weakened materially; future value depends on execution and life-cycle management, not on category novelty.

Pre-mortem

One plausible 50% downside script over three years is a slow disappointment rather than a single blowup. Toripalimab domestic sales growth falls from roughly 35%–40% today into low single digits by 2027 as the PD-1 market matures and pricing pressure intensifies. JS001sc approval slips, partner-market royalties arrive more slowly than bulls expect, and recurring losses stay stubbornly negative. The market then stops valuing Junshi on future 2027 earnings and instead values it as an expensive one-franchise commercial biotech at perhaps 6x–7x forward sales rather than around 10x. In that script, the share price could plausibly halve even without a clinical disaster.

A second downside script is financing-led. Revenue continues growing, but not fast enough to outrun R&D and debt service. Gross debt keeps rising, new milestone income does not arrive at the expected pace, and Junshi resorts to further equity financing after investors had begun to believe dilution risk was fading. In that script the damage comes from both earnings disappointment and multiple compression: the stock loses the “crossing into profitability” narrative at the same time as shareholders absorb more dilution.

Final research conclusion

Junshi is a much better business than it was when the market treated it as a story stock. Toripalimab is now a real franchise, not just a landmark approval, and management has made several disciplined choices that deserve credit: partnering overseas instead of overspending, narrowing cash burn, and preserving enough pipeline ambition to keep a second growth curve alive. The company has proved that Chinese innovation can travel farther than skeptics once allowed.

The problem at the current A-share price is not that Junshi looks broken. It is that the stock now asks investors to pay for an earnings bridge that is still only partly built. The business is approaching sustainable profitability, but the clean evidence is not yet there on a recurring basis. That makes Junshi worthy of serious attention and even ownership for investors already in the name, but it does not make the current A-share line a clear bargain. My biggest worry isn’t the science; it’s the risk that the market stays too eager to capitalize headline improvement before recurring earnings become dependable. I would change my mind in a more positive direction if Junshi posts several quarters of recurring near-profitability without help from non-recurring gains, or if a second major asset starts to generate visible economic value through approval or licensing.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: medium
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating： Hold
• One-line thesis： Commercial execution is improving fast, but recurring profitability is not yet proven and the current A-share price already discounts much of the bridge.
• Three price signals：
  • Ideal buy price： see line below
  • Acceptable hold price： CNY 34–46
  • Clearly overvalued price： CNY 57–64
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A better entry would be below CNY 27, or at a similar price only after two clean quarters of recurring near-profitability. The opportunity cost of waiting is missing a rerating if Q2–Q4 2026 confirm that the earnings bridge is real.
• Target holding horizon： 3–5 years
• Expected annualized return: conservative about -3% to 0%; base about 4% to 8%; optimistic about 13% to 18%
• Max-loss risk： around 50% in a scenario where toripalimab growth slows sharply, recurring losses persist, and the valuation compresses toward a lower commercial-biotech sales multiple
• Reassessment-trigger signals:
  • recurring net profit ex non-recurring items remains worse than -CNY 200 million for two consecutive quarters
  • toripalimab domestic quarterly sales drop below CNY 550 million
  • cash plus trading financial assets / gross debt falls below 0.60x
  • JS001sc remains without visible approval progress by 1H27
  • a new equity raise happens before recurring profitability is established

【Ideal Buy Price】25–27 CNY Basis: at least a 20% margin of safety below the CNY 31–34 value implied by the conservative scenario.

【Valuation Range】

• current: 35.88 (close as of 2026-07-24)
• bear (conservative · ideal buy zone): [25, 27]
• base (fair · acceptable hold zone): [34, 46]
• bull (optimistic · above the clearly-overvalued line): [57, 64]

Research uncertainties

I was able to verify the broad direction of sell-side optimism around Junshi’s profitability inflection, but I did not independently locate the exact Founder Securities note cited in the task card. The specific published model I verified was a Huayuan Securities note that forecast CNY 3.398 billion, 4.550 billion, and 5.780 billion of revenue for 2026–2028 and Junshi turning profitable in 2027, not 2026. That does not disprove the Founder model; it does mean I do not treat the exact Founder numbers as independently verified.

The ex-China partnering map is directionally clear, but not every country-level sublicense is easy to reconstruct from primary material. I verified the major disclosed regional deals and the fact that toripalimab is approved in more than 40 countries and regions, but I would not overstate precision around the company’s “80+ countries” commercialization-network claim without a full country-by-country reconciliation.

U.S. toripalimab economics are also inherently indirect for Junshi investors. The latest hard sales figure I verified is Coherus’s 2025 LOQTORZI net sales of $40.8 million. I did not independently verify a fresher 2026 U.S. run-rate from a primary filing during this pass, so the report avoids pretending to know more than the latest solid number.

JS001sc’s expected approval timing is partly inferential. I verified the March 2026 NMPA acceptance and the fact that Junshi still lists the asset as developmental rather than marketed as of July 2026. The “late 2026 to early 2027” timing is based on standard NMPA review timelines and should be read as an informed estimate, not company guidance.

Sources

Primary sources for this report were Junshi’s 2025 annual report, Junshi’s Q1 2026 report, Junshi’s company site and pipeline pages, Coherus SEC and press materials, Merck’s 2025 annual report, Bristol Myers’ 2025 annual report and full-year 2025 results release, Akeso’s 2025 annual results, and BeOne’s 2025 annual results announcement, together with current market-quote pages for Junshi’s A and H listings and exchange-rate data for HKD/CNY conversion.

Other tickers mentioned

• 1877.HK: Junshi’s H-share line, used to assess the A/H premium and dual-listing valuation split
• CHRS.US: U.S./Canada commercialization partner for toripalimab and source of verified LOQTORZI U.S. sales
• 9926.HK: Akeso, the closest China biotech licensing-and-immuno-oncology peer for valuation framing
• ONC.US: BeOne Medicines, the closest China-origin global oncology scale benchmark through tislelizumab and broader commercialization
• 1801.HK: Innovent, a domestic immuno-oncology peer with a broader commercial base and stronger current cash-generation profile
• MRK.US: Merck, global PD-1 benchmark through Keytruda and the best reference for franchise scale
• BMY.US: Bristol Myers Squibb, global PD-1 benchmark through Opdivo and the subcutaneous franchise-defense playbook

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.